Hemophilia A

Correction of Factor VIII Deficiency Obtained in Murine Model

Published in Gene Therapy Weekly, November 23rd, 2000

Researchers in the United States have corrected factor VIII deficiency in a murine model by targeting expression of a single chain variant of human factor VIII to epidermis.

"Hemophilia A is an X-linked bleeding disorder caused by lack of functional factor VIII protein, making it a good model disease for gene therapy," stated S. Kobayashi and colleagues from the University of Pennsylvania. "Epidermis is an attractive target tissue for gene therapy because it is accessible and gene products expressed there can enter the systemic circulation.

"Previously, we generated transgenic mice that express human B domain-deleted factor VIII in the suprabasal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2000-11-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry